Navigation Links
NJIT to host major biomedical engineering showcase and career fair
Date:2/18/2009

on on Science and Technology; New Jersey Commission on Spinal Cord Research, HealthCare Institute of New Jersey and North Jersey Partners (WIRED). Sponsorship support has been provided by the Foundation Venture Capital Group LLC; the White Rose Health Innovation Partnership; Cushman and Wakefield; Lowenstein Sandler, New Jersey Business Incubation Network, New Jersey Technology Council and Amper, Politziner and Mattia.


'/>"/>

Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. deCODE discovers cause of major subtype of glaucoma
2. Bleeding, not inflammation, is major cause of early lung infection death
3. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
4. Leading experts cite poor health and nutrition as major barrier to education in developing world
5. Majority of Americans want local action on global warming, says poll
6. How schizophrenia develops: Major clues discovered
7. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
8. NIH selects LIAI for major study on allergy molecular causes and possible treatments
9. Local sources major cause of US near-ground aerosol pollution
10. Tree of life for flowering plants reveals relationships among major groups
11. Humans not the major target of Shiga toxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Gardens, Kew and the Natural History Museum believe that ... previously thought, with many commonly grown plants such ... "meat eaters". A review paper, Murderous plants: Victorian Gothic, ... today (4 December 2009) in the Botanical Journal ...
(Date:12/4/2009)... A major discovery is challenging accepted thinking about amyloids ... and Parkinson,s and may open up a potential new ... - rope-like structures made up of proteins sometimes known as ... phases during their formation which can damage cells and cause ...
(Date:12/3/2009)... species can be likened to emptying a museum of its ... the trash, or replacing every local cuisine with McDonald,s burgers. ... not just make the world boring. New research now suggests ... some nasty disease. , "Habitat destruction and biodiversity loss,"driven by ...
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2New therapy targets for amyloid disease 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4Tyco to Report Third Quarter Results July 30 2009 50918 1CEL SCI Corporation Releases Letter to Shareholders 12919 1CEL SCI Corporation Releases Letter to Shareholders 12919 2CEL SCI Corporation Releases Letter to Shareholders 12919 3CEL SCI Corporation Releases Letter to Shareholders 12919 4CEL SCI Corporation Releases Letter to Shareholders 12919 5CEL SCI Corporation Releases Letter to Shareholders 12919 6CEL SCI Corporation Releases Letter to Shareholders 12919 7
... nearly 90 years that cancer cells commonly display ... phenomenon is not completely understood. Now, a new ... Cell reveals a functional connection between carbohydrate-driven energy ... that inhibition of a specific aspect of glucose ...
... (PNRI) and the National Institute of Standards and Technology ... connective tissues in the human breast that could shed ... possibly serve as an early warning of a heightened ... cancer is the second leading cause of cancer-related death ...
... new study in the June issue of American Naturalist, ... Santa Barbara) and Michael J. Donoghue (Yale University) explore ... cactus. , "The cactus form is often heralded as ... and function in plants," write the authors. "A succulent, ...
Other Biology News:Researchers attack tumor cells by exploiting dependency on sugar metabolism 2Links between DNA damage and breast cancer studied 2
(Date:12/7/2009)... broadens Merrimack’s capabilities to discover and develop systems biology-driven ... and technologies for cancer , ... ... -- Merrimack Pharmaceuticals, Inc., announced today that it has ... in South San Francisco, California. Hermes specializes in ...
(Date:12/6/2009)... Conn., Dec. 6 Boehringer Ingelheim today ... etexilate (150 mg BID), a direct thrombin inhibitor ... acute VTE. Results of the trial were ... Annual Meeting and simultaneously published online in the ... ,, Dabigatran etexilate met the primary outcome of ...
(Date:12/4/2009)... Stemline Therapeutics, Inc. today announced that data from pre-clinical ... both in vitro and animal models of human ... at the upcoming 51st Annual Meeting of the American Society ... December 5-8, 2009. The poster will be presented by Stemline,s ...
(Date:12/3/2009)... 3 ACCESS PHARMACEUTICALS, INC. ... update on its European commercial launch of MuGard, an ... effect of radiation treatment and chemotherapy. MuGard is commercially ... including the UK, Germany, Italy, Norway, Greece and Sweden. ...
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
... position as the largest, non-state-owned supplier of plasma-based pharmaceutical ... for 2009 of revenues of $90 to ... $100 million and net income of $18 to 22 ... --,China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China ...
... first-cycle,approval for a new molecular entity (NME) is ... average, according to a new analysis from,PAREXEL Consulting, ... PRXL ),and leading global life sciences consultancy serving ... PAREXEL Consulting,analysis, 60 percent of sales for newly-approved ...
... Detection Applications, ST. LOUIS, Oct. 15 ... of the Sigma-Aldrich Group (Nasdaq: SIAL ),today ... its electronic materials,offering with the launch of a ... new raw materials enable the,growth of scintillation detector ...
Other Biology Technology:China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 2China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 3China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 4China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xi'an Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009 5PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 2SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 3SAFC Hitech(TM) Expands Electronic Materials Portfolio With the Introduction of Scintillation Crystal Growth Halides 4
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
...
Biology Products: